AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01871740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril maleate and folic acid tablets
Description: Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
Study NCT01871740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril maleate
Description: Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
Study NCT04483388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training with Virtual Reality
Description: Computed virtual reality therapy was performed using the Nintendo Wii® console equipment. This system allows interaction with the player by means of a movement detection system and the representation of his avatar graphical representation of a user in virtual reality. It has a remote control with a wireless system, responsible for capturing the speed, direction , acceleration and deceleration of movement. The movements performed by the player are captured and reproduced on a screen via an infrared light sensor, positioned above the TV. The feedback given by the TV provides the movement itself observing opportunity in real time, generating positive reinforcement and facilitating training and improved task. The software used in this study was the Nintendo Wii Sports.
Study NCT04483388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Training
Description: It was done five types of exercises following to the protocol:~Exercise 1 (shoulder abduction); Exercise 2 (external rotation of the shoulder); Exercise 3 (elbow extension); Exercise 4 (weight transfer in upper limbs: a sitting position); Exercise 5 (function: task-oriented training).
Study NCT02086396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pumpkin seed flour
Description: The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
Study NCT02086396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (cassava flavored flour)
Description: The group placebo (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
Study NCT00488683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2-, 4-, and 12-months as IM injections in the anterolateral area of the right thigh.
Study NCT00488683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-Hib-IPV
Description: IM injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2-, 3-, and 4-months in the anterolateral area of the left thigh.
Study NCT00488683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV
Description: IM injections of 3 doses of 0.5 mL each of PCV supplied in pre-filled syringe were administered at 2-, 4-, and 12-months (Groups 2 and 3) or 13-months (Group 1) in the anterolateral area of the left thigh.
Study NCT00488683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months in the anterolateral area of the left thigh.
Study NCT00488683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib
Description: IM injection of one dose 0.5 mL of Hib supplied in pre-filled syringe was administered at 13 months in the anterolateral area of the right thigh.
Study NCT01698034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteering
Description: Weekly volunteering with elementary school children in after school programs
Study NCT01696604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2849466
Description: GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
Study NCT01696604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be available.
Study NCT00218218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: 42 mg transdermal nicotine
Study NCT00218218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21 mg transdermal nicotine
Study NCT00218218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Study NCT04593199 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gamified Smartphone App
Description: The primary objective was to determine the acceptability and satisfaction of the Draco app among children. Secondary objective was to evaluate if the Draco app could improve physical activity levels (steps, and moderate-to-vigorous physical activity) and intrinsic motivation for physical activity in children. The gamified smartphone app, Draco, is a virtual pet simulator where you care for a pet by exercising, walking, and answering healthy lifestyle questions.
Study NCT04593199 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Physical activity tracking app
Description: Participants were asked to use the Fitbit app to track and sync their daily physical activity.
Study NCT01086358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptan
Description: Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
Study NCT01086358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treximet 85Mg-500Mg Tablet
Description: Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
Study NCT04174404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICory-Circumcision
Description: The ICory-Circumcision is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children. The ICory-Circumcision programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery while the healthcare professional would receive face-to-face training on how to use the BuddyCare dashboard.
Study NCT04174404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: The routine care consists of normal consultations with the doctor, preoperative preparation, and post-operative care. During the first consultation, the child will be assessed for the need for circumcision and the doctor explains verbally to the parents about the procedure, risks, what to expect and prepare pre-operatively.
Study NCT04174404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: The routine care consists of normal consultations with the doctor, preoperative preparation, and post-operative care. During the first consultation, the child will be assessed for the need for circumcision and the doctor explains verbally to the parents about the procedure, risks, what to expect and prepare pre-operatively.
Study NCT00578292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg~Days -9 through -6
Study NCT00578292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2 Day -5 through Day -2
Study NCT00578292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: Per institutional guidelines Days -5 through -2
Study NCT00578292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg Days -5 through -2
Study NCT00578292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESNA
Description: 10 mg/kg x 5 Days -5 through -2
Study NCT00033267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT03391739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19 cells
Description: CART-19 cells treat
Study NCT02977962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy
Description: This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).
Study NCT02977962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
Study NCT02270372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONT-10, Varlilumab combination
Description: ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.~Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27.
Study NCT00921518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)
Description: 0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
Study NCT00921518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
Study NCT05376033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: root canal filling with Ceraseal sealer
Description: root canal filling with Ceraseal sealer
Study NCT05376033 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: root canal filling with Ceraseal sealer
Description: root canal filling with Ceraseal sealer
Study NCT02105961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
Study NCT02105961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile 0.9percent sodium chloride solution
Study NCT03018262 — intervention group
Intervention type: DEVICE
Intervention: TMS - sub-study 1
Description: TMS pulses will be applied to the motor hotspot of the surround muscle to identify the TMS-evoked potentials corresponding to motor surround inhibition (SI)
Study NCT03018262 — intervention group
Intervention type: DEVICE
Intervention: TMS - sub-study 2
Description: TMS will be used to stimulate the motor cortex and an inhibitory region of the inferior parietal lobe
Study NCT03018262 — intervention group
Intervention type: DEVICE
Intervention: TMS - sub-study 3
Description: TMS pulses will be delivered to the primary motor cortex at rest, at the onset of the motor task, or during the motor task
Study NCT01347411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Treatment with CPAP
Study NCT01185665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous Electrical Nerve Stimulator
Study NCT01185665 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-TENS
Description: TENS without electrical output, from the outside not different from a normal TENS
Study NCT03367078 — intervention group
Intervention type: DEVICE
Intervention: Anodal tDCS
Description: Anodal tDCS, on L-DLPFC area, is started 2 weeks after admission to the sABI Operative Unit with: one session per day (in the morning), possibly for 5 consecutive days per week (from Monday to Friday), for 2 consecutive weeks. Each tDCS session lasts 20 minutes. Current intensity is 1 mA during the first week, 2 mA in the second week
Study NCT03367078 — intervention group
Intervention type: OTHER
Intervention: Usual care
Description: Usual care of DOC patients
Study NCT01013103 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin, high vs low dose
Description: In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
Study NCT01013103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin vs Placebo
Description: In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
Study NCT03733886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10)
Description: Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level. Abbott BurstDR at default setting: Pulse width 1000 microseconds, frequency 500 Hz/40 Hz, continuous stimulation (no cycling). Pulse amplitude at maximum 60% of sensory threshold
Study NCT03733886 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10)
Description: Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level. Abbott BurstDR at default setting: Pulse width 1000 microseconds, frequency 500 Hz/40 Hz, continuous stimulation (no cycling). Pulse amplitude at maximum 60% of sensory threshold
Study NCT04195893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: Contact Lens
Study NCT04195893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Contact Lens
Study NCT02873117 — intervention group
Intervention type: OTHER
Intervention: Prostate biopsy, prostatectomy or prostate resection
Description: Collection of prostate examination
Study NCT04229407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Description: MRI eligibility evaluation Dietary supplement drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise) for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
Study NCT04229407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin B
Description: MRI eligibility evaluation vitamin B drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise)for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
Study NCT00085735 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Field Radiation Therapy
Description: Undergo smaller volume boost (involved-field radiation therapy)
Study NCT03633539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-incision Laparoscopic Surgery
Description: Patients undergo single-incision laparoscopic surgery. In this group，the surgery is performed through a transumbilical port. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
Study NCT03633539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Laparoscopic Surgery
Description: Patients undergo conventional laparoscopic surgery. In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
Study NCT00085735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00710541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ventilators designed for non invasive ventilation
Description: Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
Study NCT00746135 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device Implantation
Description: RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
Study NCT01802073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Study NCT04075734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Your Health: Self-Management + Peer Mentoring
Description: The online educational component consists of 5 self-management educational modules:~(1) Understanding Your Survivorship Care Plan; (2) Managing Your Healthcare; (3) Family and Significant Other Involvement in Your Healthcare; (4) Emotions about Your Health and Follow-Up Care; (5) Staying Healthy.~Participants will be matched with a peer mentor and complete a total of six calls. The first call is to build a rapport and identify the participant's self-management strengths, weaknesses, and goals. The next five calls align with the topic of each module, which the mentee is expected to complete prior to their scheduled call.
Study NCT04113213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Prescription (LRx)
Description: Lifestyle prescription, based on the UK WP10 medicinal prescription form. Includes advice and guidance regarding physical activity, diet, smoking and alcohol consumption.
Study NCT04009811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suersen and membraneous obturators evaluation
Description: The patient will wear one month each obturator prothesis (Suersen and membraneous obturators). The order of evaluation will be randomized in two arms.~Half of patient will first wear one month the membranous obturator then one month the Suersen, the other half of patient will first wear one month the Suersen obturator and one month the membranous obturator.
Study NCT00085735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00338871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: home exercise
Study NCT00397917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid: 4 mg versus 0.4 mg per day
Description: Folic acid
Study NCT01384149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external slt
Description: Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots
Study NCT01384149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard slt
Description: Nd:YAG LASER SLT gonioscopic laser treatment
Study NCT02428283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.
Study NCT02428283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 1 μg/kg was injected before skin incision.
Study NCT02428283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
Study NCT02428283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
Study NCT02989428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early parathyroidectomy group (EPTX-group)
Description: Participants will undergo parathyroidectomy as soon as possible
Study NCT04303039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-671
Description: ABP-671 Tablet 1.0 mg
Study NCT01905280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-resorbable membrane
Description: The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.
Study NCT01905280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix
Description: The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.